• Explore /
  • Poster
  • / Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.

Abstract Poster

Authors

Benjamin Levy

Benjamin Philip Levy

Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC

Benjamin Philip Levy , Martin Reck , James Chih-Hsin Yang , Federico Cappuzzo , Siddhartha Rawat , Jingdong Xie , Priyanka Basak , Enriqueta Felip

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05215340

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3162)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3162

Abstract #

TPS3162

Poster Bd #

148a

Abstract Disclosures

Similar Posters

First Author: Jun Miyakoshi

First Author: Panpan Zhang

First Author: Chunjiao Wu

First Author: Minal A. Barve